ExpressionEdits
Allan Bradley is currently the Chief Executive Officer at T-Therapeutics Ltd and the Co-Founder of ExpressionEdits. Previously, Allan was the Co-founder, Director, and Chief Scientific Officer at PetMedix. Allan has also held roles such as Founder, Director, and Chief Scientific Officer at Kymab Ltd and Senior Group Leader at the Wellcome Trust Sanger Institute. With a background in Genetics, Allan has made significant contributions in the field of research and biotechnology throughout their career.
ExpressionEdits
At ExpressionEdits we are redefining the status quo of protein expression. Our proprietary platform developed at University of Cambridge improves transgene expression in mammalian systems. This has direct impact on recombinant protein yields and the quality and efficacy of DNA medicines. If you think our technology can help you or you'd like to learn more about it, please get in touch: hello@expressionedits.com